Clinical Trials Sponsored by Brendan Lee

Total 1969 results

H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Breast Cancer | Breast Cancer - Female | Breast Cancer - Male

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention

Graft Versus Host Disease | GVHD

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223

Prostate Cancer | Prostate Adenocarcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene

Completed

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)

Graft-Versus-Host Disease

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene

Completed

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

Myeloma

United States
CHEOL WHAN LEE, MD, PhD.
CardioVascular Research Foundation, Korea

Completed

Comparison of Cilotax Stent and Everolimus -Eluting Stent With Diabetes Mellitus (ESSENCE-DM III)

Coronary Artery Disease

Korea, Republic of
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Terminated

Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)

Liver Cancer

United States
LEO Pharma
Bayer

Completed

Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea

Papulopustular Rosacea

United States
LEO Pharma
Bayer

Completed

Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea

Papulopustular Rosacea

United States
LEO Pharma
Bayer

Completed

A Study to Learn More About the Relationship Between the Development of a Gap in the Upper Lip (Cleft Lip) or in the Roof of the Mouth (Cleft Palate) in Newborns and the Use of Glucocorticoids by the Mother During Pregnancy: a Meta-analysis

Relationship Between the Exposure of Glucocorticoids During Pregnancy and Orofacial Cleft Development

Germany
LEO Pharma
Bayer

Completed

21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation

Healthy

United States
LEO Pharma
Bayer

Completed

Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea

Papulopustular Rosacea

United States
Evandro Chagas National Institute of Infectious...
Beatriz Grinsztejn; Thiago Torres; Valdilea Gonçalves; Brenda Hoagland

Not yet recruiting

The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir (ImPrepCab)

HIV Infections

Brazil
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Recruiting

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Melanoma Stage IV | BRAF V600 Mutation | Melanoma Stage III

United States
H. Lee Moffitt Cancer Center and Research Institute
Amgen

Active, not recruiting

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Breast Cancer | Invasive Breast Carcinoma | Invasive Ductal Breast Carcinoma | Ductal Carcinoma

United States
Lee Kirby
IWK Health Centre

Completed

Effectiveness of Wheelchair Skills Training for Caregivers of Manual Wheelchair Users

Caregivers

Canada
H. Lee Moffitt Cancer Center and Research Institute
Exelixis

Completed

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Terminated

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Bladder Cancer | Carcinoma in Situ of Bladder

United States
Lee Verweel
CapitalCare Group Inc.

Withdrawn

Medication Dispenser to Improve Care at Home for the Elderly

Cognitive Impairment | Medication Adherence
H. Lee Moffitt Cancer Center and Research Institute
Celgene

Completed

Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

Cancer of the Bile Duct

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

Cholangiocarcinoma | Gastrointestinal Tumor | Gall Bladder Carcinoma | Biliary Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)

United States
H. Lee Moffitt Cancer Center and Research Institute
Sanofi

Terminated

Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery

Pancreatic Neoplasms

United States
H. Lee Moffitt Cancer Center and Research Institute
GlaxoSmithKline

Completed

A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia

Cancer Cachexia

United States
H. Lee Moffitt Cancer Center and Research Institute
Sanofi

Terminated

Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem

Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer

Rectal Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Yoga for Aromatase Inhibitor-associated Joint Pain

Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Facts and Attitudes About Clinical Trials (FACT)

Cancer | Neoplasm

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Terminated

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

Neuroendocrine Carcinoma

United States
CHEOL WHAN LEE, MD, PhD.

Terminated

Comparison of 18-F Sodium Fluoride Uptake in Culprit Plaques Between Acute Coronary Syndrome and Stable Angina

Coronary Artery Diseases

Korea, Republic of
H. Lee Moffitt Cancer Center and Research Institute
Sanofi

Completed

Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC

Non-Small Cell Lung Cancer

United States, Germany, Puerto Rico
H. Lee Moffitt Cancer Center and Research Institute
GlaxoSmithKline

Completed

A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma

Rectal Neoplasms

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Terminated

Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas

Sarcoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement

Tobacco Dependence

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Terminated

Depocyt® With Sorafenib in Neoplastic Meningitis

Neoplastic Meningitis

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma

Glioblastoma | Anaplastic Astrocytoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Neuroendocrine Tumor | Islet Cell Tumor

United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Completed

Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

Gastric Cancer | Esophageal Cancer

United States, Puerto Rico
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Terminated

A Phase I/II Study of Sunitinib and Dacarbazine

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Dendreon

Recruiting

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Servier

Recruiting

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

United States
Sung Yong Lee
Yuhan Corporation

Recruiting

A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy (PLATINUM)

Non-small Cell Lung Cancer Stage III | Non-squamous Non-small-cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer

Korea, Republic of
H. Lee Moffitt Cancer Center and Research Institute
ImmunoRestoration

Recruiting

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

HER2-positive Breast Cancer

United States
Dr. Victor H.F. Lee

Not yet recruiting

Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma

Sinonasal Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Recruiting

Axitinib + Ipilimumab in Advanced Melanoma

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Active, not recruiting

Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

Leptomeningeal Metastases | Leptomeningeal Disease

United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Active, not recruiting

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Small-cell Lung Cancer | Small Cell Lung Cancer Extensive Stage

United States

Clinical Trials Sponsored by Brendan Lee

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations